Everyone is allowed to interpret what they wish from 10q or a conversation with an officer of a company
What can’t be denied is the that patients who received DCVAX are living significantly longer than patients on the SOC for this trial and historical SOC in other trials
All the other stuff is a diversion from the goal
The company has to rewrite a SAP to attempt to explain what happened with crossover patients , and other subgroup PTS methylated , unmethylated , SOC , SOC crossover / methylated crossovers unmethylated crossovers
These subgroups on their own can’t yield a stat sig for anyone group
But the totality of the stats for OS is likely what the SAP will try to explain
Considering that they have struggled to raise money hopefully the unblind occurs soon so they don’t have to keep diluting 10-20m shares at a time
Marzan thoughts on $AMRN Maybe u can finance the next bandaid for Linda